Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06344780
Status:
RECRUITING
Last Update Posted:
2024-04-03
First Post:
2024-03-28
Brief Title:
Abemaciclib Palbociclib or Dalpiciclib Combined With Endocrine Therapy as First-line Treatment in HR Positive HER2 Negative Unresectable or Metastatic Breast Cancer
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
A Multi-center Study of the Clinical Outcomes of Abemaciclib Palbociclib or Dalpiciclib Combined With Endocrine Therapy as First-line Treatment in HR Positive HER2 Negative Unresectable or Metastatic Breast Cancer in Real World Practice
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A multi-center real world study to evaluate the clinical outcomes and safety of Abemaciclib Palbociclib or Dalpiciclib combined with endocrine therapy as first-line treatment in HR Positive HER2 Negative unresectable or metastatic Breast Cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None